IRVINE, Calif.--(BUSINESS WIRE)--Reverse Medical Corporation announced today that it has received CE Mark (Conformité Européenne) for its RePort™ Guide Catheter System, intended to provide intracranial access during interventional neurovascular procedures. The CE Mark allows the Company to market the RePort™ Guide Catheter System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.
The RePort™ Guide Catheter System provides the neurovascular specialist with a new tool that can navigate deeply into the cerebral vascular anatomy, enabling them to treat more patients than with currently available technologies.
Commenting on this regulatory approval, Reverse Medical’s President and Chief Executive Officer, Jeffrey Valko said, “The timing for the RePort™ Guide Catheter System regulatory approval is perfect as access to the deep neurovascular anatomy is a current focus of neuro interventionalists’ interest. The various RePort™ Guide Catheter System models will enable physicians to treat a broader group of patients, helping to increase patient throughput and to enhance the economic viability of neuro labs and stroke centers worldwide.” The Company plans to commence commercialization during 2010.
Reverse Medical scientific and clinical advisor Dr. Satoshi Tateshima, MD, D.M.Sc., UCLA Interventional Neuroradiology, Ronald Reagan UCLA Medical Center, Los Angeles, CA stated, “The neurovascular anatomy often presents challenges related to fundamental access, and deep brain therapeutic microcatheter navigation support. The RePort™ Guide Catheter System design represents a game changing advancement over other guide catheters available today. The system is designed to be used across a broad range of neuro interventional procedures. The RePort™ Guide Catheter System has been designed to enable placement beyond the skull base more easily and safely than other currently available devices. I look forward to its US commercial availability in the future.”
Reverse Medical Corporation is a privately-held medical device company located in Irvine, California. The Company is focused on developing innovative neurovascular devices for improving the treatment of stroke patients, and for preventing acute stroke during carotid artery stenting procedures. The Company is working to expand its technology platform to include innovative and state-of-the art treatments for a broad spectrum of neurovascular disorders and carotid artery disease.
